Home > Boards > US OTC > Delisted > Cannabis Science Inc. (fka CBIS)

FDA approval may not be far off. Before

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
DouglasJH Member Profile
Followed By 0
Posts 872
Boards Moderated 0
Alias Born 08/28/09
160x600 placeholder
Gilead Gets FDA Approval for Remdesivir for Some Non-Hospitalized Patients
By Josh Beckerman
Top Company News of the Day
Netflix Ends Down Nearly 22%, Worst Performer in the S&P 500 and Nasdaq 100 Today -- Data Talk
2-Year Treasury Yield Rises to 0.993% This Week -- Data Talk
10-Year Treasury Yield Falls to 1.747% This Week -- Data Talk
30-Year Treasury Yield Falls to 2.062% This Week -- Data Talk
Wheat Falls as U.S.-Russia Negotiations Continue - Daily Grain Highlights
Front Month Nymex Natural Gas Fell 6.17% This Week to Settle at $3.9990 -- Data Talk
Front Month Nymex RBOB Gasoline Rose 0.97% This Week to Settle at $2.4424 -- Data Talk
GDP Seen +5.8% in 4Q -- Data Week Ahead
Canada's Omicron Infections May Have Peaked But Hospitalizations Rise, Health Officer Says
Coinbase Global Down Over 12%, on Track for Record Low Close and Record Percent Decrease -- Data Talk
EURO STOXX 50 Index Ends the Week 1.00% Lower at 4229.56 -- Data Talk
CAC 40 Index Ends the Week 1.04% Lower at 7068.59 -- Data Talk
STOXX Europe 50 Index Ends the Week 0.44% Lower at 3781.98 -- Data Talk
STOXX Europe 600 Index Ends the Week 1.40% Lower at 474.44 -- Data Talk
FTSE 100 Index Ends the Week 0.65% Lower at 7494.13 -- Data Talk
DAX Ends the Week 1.76% Lower at 15603.88 -- Data Talk
FTSE 100 Ends the Week Lower, Losing Year-to-Date Gains
Ecolab Down Nearly 6%, on Track for Largest Percent Decrease Since July 2020 -- Data Talk
Intuitive Surgical Down Nearly 7%, on Pace for Largest Percent Decrease Since April 2020 -- Data Talk
GM Expanding Production of Electric Motor Parts in NY State
Walt Disney Worst Performer in the DJIA So Far Today -- Data Talk
Glaxo Unit Valuation Boost Looks Less Likely as Unilever Walks -- Market Insight
DouglasJH   Thursday, 04/07/11 11:19:06 AM
Re: SNJgrower post# 22173
Post # of 129039 
FDA approval may not be far off. Before then you will see a rescheduling.

Rescheduling will likely happen this year. In fact, natural THC has already been rescheduled this year, as long as it mirrors the synthetic THC.

The FDA is going to be forced to make some changes....not by scientific review but by political rule.

It is possible that before FDA allows sanctioned clinical trials, CBIS gets bought before out then. Companies like Sanofi-Aventis are looking for exactly what CBIS is offering. Sanofi-Aventis even has video on youtube describing the wonders of the endocannabiniod systems and looking for generic drug to fill out there profile of products.
Highlighting innovative drugmakers' recognition of revenue-earning opportunities in the off-patented medicines market, there have been a number of deals between research and development (R&D)-focused companies and generic drugmakers in recent years. The trend to acquire generic drugmakers began when US-based Mylan outbid Israel's Teva Pharmaceutical Industries to buy Merck KGaA 's generic drug unit for US$6.9bn in 2007. Following suit, Japanese drugmaker Daiichi Sankyo purchased a controlling stake in Indian generic drugs firm Ranbaxy Laboratories in 2008. With the aim of bolstering its emerging markets portfolio, GlaxoSmithKline (GSK) announced the purchase of a minority 10-25% stake in South Africa's Aspen Pharmacare in April 2009, as well as an alliance with Indian generic drugmaker Dr Reddy's . In 2010, Novartis announced its decision to acquire Ratiopharm .

Along with its long-standing generics interest Winthrop , which is largely based in Western Europe, multinational drugmaker Sanofi-Aventis has made a number of generic drugmaker acquisitions in emerging markets as it attempts to reduce its reliance on high-revenue-earning patented drugs. We see Sanofi's strategy for external growth as a sequence of well-positioned acquisitions, enabling it to gain wider geographic coverage and, of course, increase sales.

Strengthening Its Presence In Europe's Generic Medicines Market In 2009…

In early 2009, Sanofi-Aventis closed a US$2.3bn deal to purchase Zentiva , a Czech generic medicines firm, bolstering its presence in Central and Eastern Europe.

Story at http://www.corporatefinancingweek.com/file/101220/further-deals-with-generic-drugmakers-a-possibility-for-sanofi-aventis.html

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences